(Q56447686)

English

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Esper Georges Kallas

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

11

object named as

Nathan D Wolfe

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Lisa Kierstead

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Vladimir Novitsky

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Bernard Mbewe

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Punee Pitisuttithum

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Mauro Schechter

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Miguel Aste-Amezaga

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

T Christopher Mast

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Swati B Gupta

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Alexander A Nikas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Danilo R Casimiro

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Walter L Straus

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

John W Shiver

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

0 references

publication date

17 November 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

950-957

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Adenoviruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Neutralizing antibodies against 33 human adenoviruses in normal children in Rome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Age-related decrease in adenovirus-specific T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Viral vectors in malaria vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.10.145

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56447686&oldid=2081764237"